Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Identifieur interne : 000838 ( Istex/Curation ); précédent : 000837; suivant : 000839Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Auteurs : Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-11.
English descriptors
- KwdEn :
Abstract
Long‐term treatment with levodopa in Parkinson's disease results in the development of motor fluctuations, including reduced duration of antiparkinsonian action and involuntary movements, i.e., levodopa‐induced dyskinesia. Cannabinoid receptors are concentrated in the basal ganglia, and stimulation of cannabinoid receptors can increase γ‐aminobutyric acid transmission in the lateral segment of globus pallidus and reduce glutamate release in the striatum. We thus tested the hypothesis that the cannabinoid receptor agonist nabilone (0.01, 0.03, and 0.10 mg/kg) would alleviate levodopa‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine hydrochloride (MPTP) ‐lesioned marmoset model of Parkinson's disease. Coadministration of nabilone (0.1 mg/kg) with levodopa was associated with significantly less total dyskinesia (dyskinesia score, 12; range, 6–17; primate dyskinesia rating scale) than levodopa alone (22; range, 14–23; P < 0.05). This effect was more marked during the onset period (0–20 minutes post levodopa). There was no reduction in the antiparkinsonian action of levodopa. Furthermore, the intermediate dose of nabilone used (0.03 mg/kg) increased the duration of antiparkinsonian action of levodopa by 76%. Thus, cannabinoid receptor agonists may be useful in the treatment of motor complications in Parkinson's disease. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10289
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000838
Links to Exploration step
ISTEX:0D72950B7DD74740B4CC2AF207D9BF963CD0F918Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation wicri:level="1"><mods:affiliation>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Oxford Road, Manchester, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Oxford Road, Manchester</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Current Address: Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Current Address: Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea></affiliation></author><author><name sortKey="Henry, Brian" sort="Henry, Brian" uniqKey="Henry B" first="Brian" last="Henry">Brian Henry</name><affiliation wicri:level="1"><mods:affiliation>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Oxford Road, Manchester, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Oxford Road, Manchester</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Current Address: Organon Laboratories Limited, Lanarkshire, Scotland, ML1 5SH, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Current Address: Organon Laboratories Limited, Lanarkshire, Scotland, ML1 5SH</wicri:regionArea></affiliation></author><author><name sortKey="Hill, Michael" sort="Hill, Michael" uniqKey="Hill M" first="Michael" last="Hill">Michael Hill</name><affiliation wicri:level="1"><mods:affiliation>Motac Neuroscience Ltd., Manchester Science Park, Manchester, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd., Manchester Science Park, Manchester</wicri:regionArea></affiliation></author><author><name sortKey="Crossman, Alan" sort="Crossman, Alan" uniqKey="Crossman A" first="Alan" last="Crossman">Alan Crossman</name><affiliation wicri:level="1"><mods:affiliation>Motac Neuroscience Ltd., Manchester Science Park, Manchester, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd., Manchester Science Park, Manchester</wicri:regionArea></affiliation></author><author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name><affiliation wicri:level="1"><mods:affiliation>Motac Neuroscience Ltd., Manchester Science Park, Manchester, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd., Manchester Science Park, Manchester</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0D72950B7DD74740B4CC2AF207D9BF963CD0F918</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10289</idno><idno type="url">https://api.istex.fr/document/0D72950B7DD74740B4CC2AF207D9BF963CD0F918/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000838</idno><idno type="wicri:Area/Istex/Curation">000838</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation wicri:level="1"><mods:affiliation>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Oxford Road, Manchester, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Oxford Road, Manchester</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Current Address: Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Current Address: Walton Centre for Neurology and Neurosurgery, Liverpool</wicri:regionArea></affiliation></author><author><name sortKey="Henry, Brian" sort="Henry, Brian" uniqKey="Henry B" first="Brian" last="Henry">Brian Henry</name><affiliation wicri:level="1"><mods:affiliation>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Oxford Road, Manchester, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Oxford Road, Manchester</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Current Address: Organon Laboratories Limited, Lanarkshire, Scotland, ML1 5SH, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Current Address: Organon Laboratories Limited, Lanarkshire, Scotland, ML1 5SH</wicri:regionArea></affiliation></author><author><name sortKey="Hill, Michael" sort="Hill, Michael" uniqKey="Hill M" first="Michael" last="Hill">Michael Hill</name><affiliation wicri:level="1"><mods:affiliation>Motac Neuroscience Ltd., Manchester Science Park, Manchester, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd., Manchester Science Park, Manchester</wicri:regionArea></affiliation></author><author><name sortKey="Crossman, Alan" sort="Crossman, Alan" uniqKey="Crossman A" first="Alan" last="Crossman">Alan Crossman</name><affiliation wicri:level="1"><mods:affiliation>Motac Neuroscience Ltd., Manchester Science Park, Manchester, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd., Manchester Science Park, Manchester</wicri:regionArea></affiliation></author><author><name sortKey="Brotchie, Jonathan" sort="Brotchie, Jonathan" uniqKey="Brotchie J" first="Jonathan" last="Brotchie">Jonathan Brotchie</name><affiliation wicri:level="1"><mods:affiliation>Motac Neuroscience Ltd., Manchester Science Park, Manchester, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Motac Neuroscience Ltd., Manchester Science Park, Manchester</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-11">2002-11</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1180">1180</biblScope><biblScope unit="page" to="1187">1187</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0D72950B7DD74740B4CC2AF207D9BF963CD0F918</idno><idno type="DOI">10.1002/mds.10289</idno><idno type="ArticleID">MDS10289</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MPTP</term><term>Parkinson's disease</term><term>cannabinoid</term><term>dyskinesia</term><term>nabilone</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Long‐term treatment with levodopa in Parkinson's disease results in the development of motor fluctuations, including reduced duration of antiparkinsonian action and involuntary movements, i.e., levodopa‐induced dyskinesia. Cannabinoid receptors are concentrated in the basal ganglia, and stimulation of cannabinoid receptors can increase γ‐aminobutyric acid transmission in the lateral segment of globus pallidus and reduce glutamate release in the striatum. We thus tested the hypothesis that the cannabinoid receptor agonist nabilone (0.01, 0.03, and 0.10 mg/kg) would alleviate levodopa‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine hydrochloride (MPTP) ‐lesioned marmoset model of Parkinson's disease. Coadministration of nabilone (0.1 mg/kg) with levodopa was associated with significantly less total dyskinesia (dyskinesia score, 12; range, 6–17; primate dyskinesia rating scale) than levodopa alone (22; range, 14–23; P < 0.05). This effect was more marked during the onset period (0–20 minutes post levodopa). There was no reduction in the antiparkinsonian action of levodopa. Furthermore, the intermediate dose of nabilone used (0.03 mg/kg) increased the duration of antiparkinsonian action of levodopa by 76%. Thus, cannabinoid receptor agonists may be useful in the treatment of motor complications in Parkinson's disease. © 2002 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000838 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000838 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:0D72950B7DD74740B4CC2AF207D9BF963CD0F918
|texte= Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |